Lexeo laid off 15% of staff in April to focus on lead cardiac gene therapies
Lexeo Therapeutics laid off 15% of its staff last month as part of a wider plan to siphon $20 million from its wider pipeline to fund the gene therapy biotech’s lead cardiac programs.
Lexeo Therapeutics laid off 15% of its staff last month as part of a wider plan to siphon $20 million from its wider pipeline to fund the gene therapy biotech’s lead cardiac programs.
